Sorafenib (S) with preoperative chemoradiotherapy for extremity soft tissue sarcomas (STS) and evaluation by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

Abstract

TPS335 Background: We previously reported on the treatment of AJCC stage III extremity STS with 3 cycles of preoperative epirubicin/ifosfamide (E/I) and hypofractionated radiation (RT) followed by 3 cycles of E/I after resection (Ryan et al., Cancer 2008). Phase II studies have shown single-agent activity of S in advanced sarcoma. We hypothesize that the addition of S to our chemoradiotherapy regimen is safe and will improve outcomes by potentiating the effects on the local tumor and enhancing the effects on micrometastatic disease. DCE-MRI is a functional imaging modality that can detect changes in blood flow and/or vessel wall permeability within a tumor. The “Shutter-Speed” Model (SSM) (Li et al., Magn Reson Med 2005) is a unique method of quantitative DCE-MRI data analysis that is more accurate in estimating pharmacokinetic parameters such as Ktrans and ve compared to the conventional Tofts' model (Tofts et al., J Magn Reson Imaging 1999). These biomarkers may be useful in early assessment of activity...